Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study.

NCT03360890 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT03360890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03360890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study.
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 26, 2018
Completion date
September 30, 2032
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

salivary gland cancer, thyroid cancer